CAPR 240920 2.50P (CAPR240920P2500) Stock Options, News & Quotes

0.05
-0.10-66.67%

15min DelayClose Sep 12 16:00 ET

0.05High0.05Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

angel beginner

Aug 22 07:24

$Capricor Therapeutics (CAPR.US)$ Is this a short squeeze or what?

101764688

Aug 8 18:00

APR MORTAGAGE PRINCIPAL

APR MIROR SUDDENLY YOU SEARCH THE POWERED TO PROVIDER COME FROM YOU BUDDY'S THIS IS WHAT'S HAPPENED I RICH' MARGIN INTO SYNDICATED IN HAVANA PUBLIC MONEY LIBRARY
MORTAGAGE • Even Year 1 Of The Month issuance not Telle . This should have been more Monitoring sys Will Running You Buddy's Rich Into The LINE (2) Opt-imum Making TAGGED 1 Line 25.71% other one 35.29%
Tp. RNR L $Providence Gold Mines Inc (PHD.CA)$
Sulferina Floats Fish Vitamins
Come Colleapse In front desk $PCB Bancorp (PCB.US)$
...

101764688's badges

Palantir Q2 revenue beats, guidance attracting post market buying

MARKET-TEST-DUMMY

Jul 16 06:44

👁

$Capricor Therapeutics (CAPR.US)$

Trytosaveabit

Jun 28 08:14

Make a note!

$Capricor Therapeutics (CAPR.US)$ Capricor Therapeutics Inc: Pre-Bla Meeting With FDA Scheduled for Q3 2024 to Discuss Options to Expedite Bla Filing

Jaguar8

Jun 11 12:07

NEWS

$Capricor Therapeutics (CAPR.US)$
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway
Capricor Therapeutics (NASDAQ: CAPR) announced a successful Type-B meeting with the FDA for their lead asset, CAP-1002, aimed at treating Duchenne muscular dystrophy (DMD). The FDA approved a rolling Biologics License Application (BLA) submission, set to begin in Q3 2024. The rolling BLA process could stream...